Unknown

Dataset Information

0

Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics


ABSTRACT: Background The biomarker fibroblast growth factor-23 (FGF-23) has been associated with increased cardiovascular morbidity and mortality in both patients with and without type 2 diabetes. The aim of this study was to evaluate the relationship between FGF-23 and cardiac structure, function and perfusion in patients with type 2 diabetes and normal or mildly impaired kidney function. Furthermore, to investigate the association between FGF-23, anti-diabetes therapy and the classic complications and risk factors associated with type 2 diabetes. Methods In this cross-sectional study, 246 patients with type 2 diabetes underwent echocardiography and advanced cardiac magnetic resonance imaging to assess left ventricular (LV) structure and function. In addition, myocardial blood flow (MBF) during rest and pharmacological stress (adenosine 140 µg/kg/min) were evaluated in 183 of the patients. Patients with eGFR?

SUBMITTER: Sørensen M 

PROVIDER: S-EPMC7528463 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5051268 | biostudies-literature
| S-EPMC3669677 | biostudies-literature
| S-EPMC3386678 | biostudies-literature
| S-EPMC5818994 | biostudies-literature
| S-EPMC2637204 | biostudies-literature
| S-EPMC6171267 | biostudies-literature
| S-EPMC3904568 | biostudies-literature
| S-EPMC8912769 | biostudies-literature
| S-EPMC6044452 | biostudies-literature
| S-EPMC6098163 | biostudies-literature